Jian Liu

WORK HISTORY

EDUCATION

ABOUT JIAN LIU

Dr. Liu is currently the President of Drug Discovery Division at Shanghai Medicilon Inc. Previously he was the chief executive officer of Silexon AI where AI empowers the life science and drug discovery. Before that, he was the CSO and site head at Eternity Bioscience Inc, the Hengrui Medicine US R&D center located in Cranbury New Jersey, in charge of drug innovation. Dr. Jian Liu obtained a Ph.D. degree in organic chemistry from UCLA in 1998 and did two postdoc researches afterwards at UC Irvine and University of Pennsylvania. He joined the medicinal chemistry department in Merck Research Laboratory at Rahway site in February 2001. Dr. Liu has worked on and managed projects from target validation, lead identification, and lead optimization to generate multiple preclinical candidates which went to first in human, phase I, phase II clinic trials. Dr. Liu is an expert in drug discovery for many therapeutic areas such as osteoporosis, obesity, diabetes, cardiovascular disease, rheumatoid arthritis, oncology, pain and infection disease. Dr. Liu has been also in charge of outsourcing effort with several external companies. Based on his research work, Dr. Liu has published over 90 peer reviewed papers, patents and patent applications. Dr. Liu had worked as a lecturer at Tsinghua University for four years before he moved to the US. Dr. Liu also volunteered as an Executive Council member of Sino-American Pharmaceutical Professionals Association (SAPA) and was SAPA 25th president in 2018. He is currently a board of director member of SAPA. Dr. Liu was honored as the 2019 Outstanding 50 Asian American in Business awardee. He joined Silexon AI in July of 2022.